Ulrich Jehn

TL;DR: This study indicates that the AIDA protocol is a well-tolerated regimen that induces molecular remission in almost all patients with PML/RARα-positive APL and suggests that a remarkable cure rate can be obtained with this treatment.

TL;DR: Intention-to-treat analysis revealed that the 4-year disease-free survival (DFS) rate of patients with a donor versus those without a donor was 52.2% versus 42.2%, and the strategy to perform early allo-SCT led to better overall results than auto-S CT, especially for younger patients or those with bad/very bad risk cytogenetics.

TL;DR: In this article, the effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to intensive chemotherapy in patients of 61 years and older with untreated newly diagnosed acute myeloid leukemia (AML) were compared.

TL;DR: Endothelial damage as a result of cellular activation and subsequent release of cytokines in the course of a aGVHD, which is not inhibited by CsA prophylaxis is suggested, while severe microangiopathy was observed in ten patients and was fatal in seven.

TL;DR: It is concluded that although priming with G- CSF can improve the CR rate, the use of G-CSF during and/or after chemotherapy has no effect on the long-term outcome of AML in older patients.